The estimated Net Worth of Jim Robinson is at least $737 mil dollars as of 9 January 2008. Jim Robinson owns over 5,000 units of Novavax stock worth over $737,400 and over the last 17 years Jim sold NVAX stock worth over $0.
Jim has made over 2 trades of the Novavax stock since 2007, according to the Form 4 filled with the SEC. Most recently Jim bought 5,000 units of NVAX stock worth $15,350 on 9 January 2008.
The largest trade Jim's ever made was buying 20,000 units of Novavax stock on 21 August 2007 worth over $62,400. On average, Jim trades about 5,000 units every 28 days since 2007. As of 9 January 2008 Jim still owns at least 60,000 units of Novavax stock.
You can see the complete history of Jim Robinson stock trades at the bottom of the page.
Jim's mailing address filed with the SEC is C/O NOVAVAX, INC., 9920 BELWARD CAMPUS DRIVE, ROCKVILLE, MD, 20850.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi y Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: